The Motley Fool

Integral Diagnostics Ltd (ASX:IDX) announces profit upgrade and new acquisitions

The Integral Diagnostics Ltd (ASX: IDX) share price was 2% up to $2.85 on Friday, following a market update from the company which specialises in medical imaging services, before falling back to $2.79 in today afternoon’s trade.

Integral Diagnostics confirmed its guidance for FY18. Normalised net profit after tax is expected to grow 20% from the $15 million reported in the previous year, with EBITDA in the range of $38 million to $39 million.

In February, the company rejected a $312 million scrip bid from rival Capitol Health Ltd (ASX: CAJ). Since then, the Integral Diagnostics share price has gained 30%, and now the current market capitalisation of the company amounts to $411 million.

Integral Diagnostics has transformed from being a takeover target to making acquisitions. A few days ago, the company announced the purchase of three radiology practices in Auckland for $98 million. Today it’s the turn of Victoria-based Geelong Medical Imaging, for $5 million.

The transactions had an expected FY19 EBITDA contribution of between $13 million and $14 million, and will increase the company’s presence in Australia and New Zealand to 53 radiology clinics, including 13 hospital sites.

Based on the company’s forecast, the stock trades at 22x FY18 earnings.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Tommaso Autorino has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here’s the best part: we think there’s one ASX stock that’s uniquely positioned to profit immensely from this explosive new industry… taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more